Skip to content Skip to footer

Pulmonology

Advancing the Future of
Pulmonology

The studies listed below have helped generate the evidence needed to advance respiratory research and pave the way for improved treatment options for patients with lung diseases.

Active Studies
0
Recruiting
0
Therapeutic Areas
0
Past Studies

Helping Shape Tomorrow's Respiratory Treatments

Respiratory diseases can affect every aspect of daily life, turning simple activities like climbing stairs, exercising, or even breathing comfortably into ongoing challenges. At Zillan Clinical Research, we have had the privilege of working with individuals who chose to participate in pulmonology studies aimed at advancing care for conditions such as asthma and other chronic lung diseases. Each completed trial has contributed valuable knowledge to the scientific community, helping deepen our understanding of respiratory disease and bringing us one step closer to more effective treatment options for future patients.

Completed Studies

At Zillan Clinical Research, the pulmonology studies listed below were completed in collaboration with leading pharmaceutical and biotechnology partners, generating valuable clinical data that supports ongoing progress in respiratory medicine and the development of improved future treatment options for patients with chronic and acute lung conditions.

PULMONOLOGY

About Eosinophilic Asthma Clinical Trials

Eosinophilic asthma is a chronic inflammatory lung condition that can lead to frequent symptoms and poor disease control despite standard treatment. Zillan Clinical Research conducted two randomized, double-blind, placebo-controlled studies evaluating dexpramipexole in adolescents and adults with eosinophilic asthma. The trials assessed lung function, symptom control, and exacerbation outcomes to support further research in eosinophilic asthma management.

Not Recruiting

Current Status

Eosinophilic Asthma

Condition

Endocrinology

Lorem Ipsum is simply dummy text.

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since 1966, when designers at Letraset and James Mosley, the librarian at St Bride Printing Library, took a 1914 Cicero translation and scrambled it.

Not Recruiting

Current Status

Lorem Ipsum

Condition